moderna inc assured this Tuesday that his flu shot did not meet the initial success criteria in a test of last phasewhich sent its shares down almost a 5% before the opening of the session.
At the time of an interim analysis of the trial, which compared the vaccine with another already approved, not enough people had been infected with the flu, so it was too early to determine the effectiveness of the modern vaccineaccording to the company, which added that it would continue testing it to obtain more data.
The company trusts success of your flu vaccine and aspires to take over a large part of the markets of the respiratory syncytial virus (RSV) and the seasonal flu with their new mRNA vaccines.
In February, modern forecast sales of covid-19 vaccines of US$5 billion this year, much less than the US$18.4 billion that is expected to be obtained in 2022, due to the decrease in the demand for vaccines.
vaccination
Argentina.gov
Investors expected stronger data on the anti-flu vaccine after an earlier trial showed that it generated a strong immune response against the influenza A strainsbut it was inferior to an approved vaccine for the least prevalent strain of the flu B.
“We would have liked the study to stop sooner for non-inferiority”he claimed michael yeea Jefferies analyst, in a research note.
flu vaccination.jpg
Earlier this year, the experimental messenger RNA vaccine of modern, mRNA-1345against him respiratory syncytial virus (RSV) had an efficacy of 84% in the prevention of at least two symptoms in older adults. modern said he hopes to submit the application for approval of his RSV vaccine This trimester.
modern expects to bill between US$8,000 and US$15,000 million with its combined portfolio of respiratory vaccines in 2027. He is testing vaccines against RSVthe flu and one covid-19 injection of a new generation in advanced phase studies. Meanwhile, he affirms that he hopes to launch six shots important in the coming years.
moderna.webp
The flua infection of the nose, throat and lungs, kills between 290,000 and 650,000 people a year worldwide.
Source: Ambito
